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OBJECTIVE — The purpose of this study was to assess the glucose-lowering efﬁcacy and
safety of rimonabant monotherapy in drug-naive type 2 diabetic patients.
RESEARCH DESIGN AND METHODS — The Study Evaluating Rimonabant Efﬁcacy
in Drug-Naive Diabetic Patients (SERENADE) was a 6-month, randomized, double-blind,
placebo-controlled trial of 20 mg/day rimonabant in drug-naive patients with type 2 diabetes
(A1C 7–10%). The primary end point was A1C change from baseline; secondary end points
included body weight, waist circumference, and lipid proﬁle changes.
RESULTS — A total of 281 patients were randomly assigned; 278 were exposed to treatment,
and 236 (84.9%) completed the study. Baseline A1C (7.9%) was reduced by 0.8% with
rimonabantversus0.3%withplacebo(A1C0.51%;P0.0002),withalargerrimonabant
effect in patients with baseline A1C 8.5% ( A1C 1.25%; P  0.0009). Weight loss from
baseline was 6.7 kg with rimonabant versus 2.8 kg with placebo ( weight 3.8 kg; P 
0.0001). Rimonabant induced improvements from baseline in waist circumference (6 vs. 2
cm; P  0.0001), fasting plasma glucose (0.9 vs. 0.1 mmol/l; P  0.0012), triglycerides
(16.3vs.4.4%;P0.0031),andHDLcholesterol(10.1vs.3.2%;P0.0001).Adverse
events of interest that occurred more frequently with rimonabant versus placebo were dizziness
(10.9 vs. 2.1%), nausea (8.7 vs. 3.6%), anxiety (5.8 vs. 3.6%), depressed mood (5.8 vs. 0.7%),
and paresthesia (2.9 vs. 1.4%).
CONCLUSIONS — Rimonabantmonotherapyresultedinmeaningfulimprovementsingly-
cemic control, body weight, and lipid proﬁle in drug-naive type 2 diabetic patients. Further
ongoingstudieswillbetterestablishthebeneﬁt-to-riskproﬁleofrimonabantanddeﬁneitsplace
in type 2 diabetes management.
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A
n increasing worldwide burden of
type 2 diabetes is being driven by
the obesity epidemic (1,2). Studies
suggest that abdominal obesity may play
an important role in the pathogenesis of
multiple cardiometabolic risk factors
present in type 2 diabetes, which contrib-
ute substantially to the increased cardio-
vascular risk in this population (3–5).
Comprehensive type 2 diabetes man-
agement involves glucose, lipid, and
blood pressure control, often requiring
multiple pharmacotherapies plus lifestyle
changes to achieve weight loss (6). How-
ever, weight loss is generally more difﬁ-
cult in type 2 diabetic patients; moreover,
thiazolidinediones,sulfonylureas,andin-
sulin cause weight gain, whereas met-
formin and incretin-related therapies
tend to be weight neutral or induce mod-
est weight loss (7–11).
The endocannabinoid system regu-
lates energy homeostasis and lipid and
glucose metabolism through G protein–
coupled cannabinoid (CB1) receptors lo-
cated in the brain, adipose tissue, liver,
skeletal muscle, and pancreas (12,13).
CB1 antagonism in these tissues directly
modulates fat deposition in liver and ad-
ipose tissue, fatty acid synthesis, and glu-
cosedisposal(12,13)andmayrepresenta
potential drug target for type 2 diabetes
(14).
Rimonabant, a selective CB1 receptor
antagonist, has been shown to reduce
body weight and improve glycemic con-
trol in overweight/obese patients with
type 2 diabetes suboptimally controlled
with metformin or sulfonylurea mono-
therapy (15). We report the results of the
Study Evaluating Rimonabant Efﬁcacy in
Drug-Naive Diabetic Patients (SERE-
NADE),anexploratorystudytoassessthe
glucose-lowering efﬁcacy and safety of
rimonabant monotherapy in drug-naive
type 2 diabetes and the ﬁrst trial to use
A1C as the primary end point.
RESEARCH DESIGN AND
METHODS
Patients
This randomized, double-blind, parallel-
group, placebo-controlled, multinational
study recruited patients from 56 centers
(22 March 2005–10 June 2006). Eligible
type 2 diabetic (16) patients were aged
18 years with duration of diabetes
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7 and 10%. Prior use of oral antidia-
betic agents was not permitted within 6
months of screening and only for 4
months in duration. Exclusion criteria in-
cluded weight loss 5 kg within the pre-
vious 3 months, pregnancy or lactation,
use of antiobesity treatments within the
previous 3 months, changes to lipid-
modifyingtreatmentswithintheprevious
2 months, and any clinically signiﬁcant
disorders (endocrine/metabolic/severe
psychological disorders, presence/history
of cancer, or laboratory abnormalities).
Patients with a history of depression were
not excluded from this study.
The study protocol was approved by
institutional review boards/independent
ethics committees at each site to comply
with the Declaration of Helsinki. All pa-
tientsprovidedwritteninformedconsent.
Study design
Aftera1-to2-weekscreeningperiodwith
instructions not to change diet, patients
were randomly assigned to double-blind
rimonabant (20 mg) or matching placebo
(1:1 ratio) for 6 months. Randomization
was stratiﬁed according to A1C at screen-
ing(7to8.5%or8.5to10%).All
patients received American Diabetes As-
sociation dietary recommendations (6)
from a dietitian at baseline and reinforce-
ment at the 3- and 6-month study visits.
Overweight (BMI 27 to 30 kg/m
2)o r
obese (BMI 30 kg/m
2) patients were in-
structed to follow a 600-kcal/day caloric
deﬁcit. All patients were encouraged to
increase physical activity.
The primary study end point was ab-
solute change in A1C from baseline to
study end (month 6). Prespeciﬁed sec-
ondary efﬁcacy parameters, as in any an-
tidiabetestrial,includedtheproportionof
patients achieving predeﬁned glycemic
targets (A1C 6.5 or 7%) and changes
in fasting plasma glucose (FPG), body
weight,waistcircumference,HDLcholes-
terol, triglycerides, LDL particle size, fast-
ing insulin, homeostasis model
assessment of insulin resistance (HOMA-
IR), homeostasis model assessment of
-cellfunction,adiponectin,leptin,ghre-
lin, blood pressure, and urinary albumin-
to-creatinineratio(17).PatientswithA1C
9% at 3 months conﬁrmed by a repeat
measurement 1 month later could receive
rescue medication at the investigator’s
discretion.
Measurements
Primary and secondary efﬁcacy parame-
ters were measured at screening and/or
baseline and at 3 and 6 months after ran-
dom assignment. Body weight and vital
signsweremeasuredatscreening,atbase-
line, and monthly thereafter.
Blood samples for measurement of
metabolic parameters were taken under
fasting conditions and were analyzed at a
central laboratory (MDS Diagnostic Ser-
vices, Mississauga, ON, Canada). A1C
was measured using ion-exchange high-
pressure liquid chromatography with Di-
abetes Control and Complications Trial
reference values.
Safety analyses were based on stan-
dard adverse event reporting. All adverse
events were coded using the global Med-
ical Dictionary for Regulatory Activities
(MedDRA) (version 9.0). Adverse events
were analyzed using MedDRA by system
organ classiﬁcation and the subcategory,
preferred term (which represents a single
medical concept). Unblinded safety data
were evaluated in an ongoing manner by
anindependentdatamonitoringcommit-
tee.Duringeachvisit,investigatorsuseda
questionnaire of scripted neurological
and psychiatric questions (see online Ap-
pendix A, available at http://dx.doi.org/
10.2337/dc08-0386). Any adverse event
related to a depressive disorder or neuro-
logical adverse event was captured by pa-
tients self-reporting the event to the
investigator and recorded in a standard
adverse event/serious adverse event form
foreachepisode;aquestionnairewasthen
completed and the adverse event or /seri-
ous adverse event was coded using Med-
DRA terminology. Symptoms were only
recorded when the diagnosis was un-
known. Any adverse event or serious ad-
verse event reported within 75 days of
the last study drug dose was included in
the safety database. Hypoglycemia was
deﬁned as clinical symptoms consistent
with hypoglycemia, with or without a
conﬁrmatory blood glucose measurement.
Statistical analysis
Samplesizecalculationswerebasedonan
assumed difference in A1C of 0.8% be-
tween the 20 mg rimonabant and placebo
groups at 6 months (SD for the change in
A1C from baseline of 1.6%). A sample
size of 132 patients per group was esti-
mated to provide 95% power to detect
this treatment difference, with a two-
sided signiﬁcance level of 0.05, assuming
an overall study dropout rate of 20%. An
intention-to-treat (ITT) analysis (primary
analysis) was conducted using last obser-
vation carried forward. The ITT popula-
Table 1—Demographic and disease characteristics at baseline
Placebo
20 mg
rimonabant
n 140 138
Age (years) 55.5  10.4 57.8  10.5
Male sex 46.4 52.9
Race
White 84.3 84.1
Black 3.6 2.2
Asian/Oriental 0.7 1.4
Other 11.4 12.3
Body weight (kg) 96.3  21.0 96.6  21.1
BMI (kg/m
2) 34.6  6.9 34.4  6.6
27 89.3 89.9
30 72.9 72.5
Waist circumference (cm) 108.8  14.8 108.7  13.6
High waist circumference (% men/%
women)*
70.8/88.0 66.7/90.8
Diabetes duration (months) 15.1  13.4 16.0  11.2
Family history of type 2 diabetes 52.1 46.4
A1C (%) 7.9  0.7 7.9  0.8
A1C 8.5 and 10 25.7 25.4
FPG (mmol/l) 8.7  1.9 9.0  1.9
Concomitant antidyslipidemia medication 35.7 29.7
Concomitant antihypertensive medication 67.1 62.3
Data are means  SD or %. *Waist circumference 102 cm (men) or 88 cm (women).
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Placebo 20 mg rimonabant P value vs. placebo
A1C
All patients
n 131 130
Mean baseline (%)* 7.9  0.7 7.9  0.8
Mean change vs. baseline (%)* –0.3  1.2 –0.8  1.2
LS mean change vs. placebo (%)† — –0.51  0.14 0.0002
A1C 6.5% at 6 months 16.0 (21) 23.8 (31) 0.0930
A1C 7.0% at 6 months 35.1 (46) 50.8 (66) 0.0122
Patients with A1C 8.5%
n 31 34
Mean baseline (%)* 8.9  0.3 8.9  0.5
Mean change vs. baseline (%)* –0.7  1.7 –1.9  1.1
LS mean change vs. placebo (%)† — –1.25  0.36 0.0009
Fasting plasma glucose (mmol/l)
n 126 123
Mean baseline* 8.6  1.7 9.1  2.0
Mean change vs. baseline* 0.1  2.1 –0.9  2.3
LS mean change vs. placebo† — –0.83  0.25 0.0012
Body weight (kg)
n 138 135
Mean baseline* 96.0  20.9 96.6  21.1
Mean change vs. baseline* –2.8  4.8 –6.7  5.5
LS mean change vs. placebo† — –3.84  0.61 0.0001
Waist circumference (cm)
n 131 129
Mean baseline* 108  15 109  14
Mean change vs. baseline* –2  5– 6  6
LS mean change vs. placebo† — –3.7  0.7 0.0001
Adiponectin (	g/ml)
n 128 127
Mean baseline* 6.0  3.9 5.5  3.3
Mean change vs. baseline* –0.2  2.9 1.6  4.0
LS mean change vs. placebo† — 1.60  0.41 0.0001
HOMA-IR
n 126 119
Mean baseline* 7.1  5.8 7.8  8.9
Mean change vs. baseline* 0.3  7.6 –1.9  7.7
LS mean change vs. placebo† — –1.9  0.7 0.0098
Proinsulin/insulin
n 128 126
Mean baseline* 0.59  0.36 0.63  0.49
Mean change vs. baseline* –0.04  0.39 –0.17  0.43
LS mean change vs. placebo† — –0.10  0.04 0.0135
HDL cholesterol (mmol/l)
n 131 130
Mean baseline* 1.29  0.28 1.31  0.33
Mean % change vs. baseline* 3.15  12.16 10.05  17.04
LS mean % change vs. placebo† — 7.30  1.75 0.0001
Triglycerides (mmol/l)
n 131 129
Mean baseline* 2.09  1.02 2.35  1.64
Mean % change vs. baseline* 4.35  58.12 –16.33  32.76
LS mean % change vs. placebo† — –17.28  5.78 0.0031
LDL cholesterol (mmol/l)
n 131 130
Mean baseline* 3.31  0.85 3.41  0.93
Mean % change vs. baseline* 1.35  28.14 –1.80  26.04
LS mean % change vs. placebo† — –1.475  3.147 0.6396
Continued on following page
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at least one dose of double-blind treat-
mentandhadatleastoneassessmentafter
random assignment. All efﬁcacy data ob-
tained after the introduction of rescue
medication were excluded from the anal-
ysis. The safety population included all
patients randomly assigned and exposed
to treatment. For descriptive data for
adverse events, statistical analyses were
not performed; descriptive data were re-
ported using numbers and percentages of
patients.
Statistical analyses were performed us-
ing SAS (version 8.2, SAS Institute, Cary,
NC). Continuous variables were measured
using repeated-measures ANCOVA, with
treatment, country, and randomization
stratum as ﬁxed effects and baseline assess-
mentasthecovariate.Categoricaldatawere
analyzedusingaCochran-Mantel-Haenszel
test stratiﬁed on country and randomiza-
tion stratum. P values were two sided and
unadjusted.
RESULTS— In total, 281 patients
were randomly assigned to 20 mg rimon-
abant (n  140) or placebo (n  141)
(supplemental Fig. 1, available in the on-
line appendix). Two patients in the
rimonabant group and one in the placebo
groupdidnotreceivestudytreatmentand
were excluded from the efﬁcacy set. The
ITT efﬁcacy population comprised 130
and 131 patients in the rimonabant and
placebo groups, respectively. Of the 278
patients randomly assigned and exposed
to treatment, 236 patients (84.9%) com-
pleted the study: 80.4 and 89.3% in the
rimonabant and placebo groups, respec-
tively. Overall, 27 patients receiving
rimonabant discontinued treatment (ad-
verse events 13, patient request 8, lost to
follow-up 2, poor compliance 1, and
otherreasons3)versus15patientsreceiv-
ing placebo (lack of efﬁcacy 4, lost to fol-
low-up 4, adverse events 3, patient
request 3, and other reasons 1). Rescue
medication was required for four patients
(2.9%) in the rimonabant group and 14
patients (10.0%) in the placebo group.
Treatment groups were well balanced
for demographic and baseline disease
characteristics (Table 1). Mean baseline
A1C was 7.9%, and most participants
were overweight or obese (90% had BMI
27kg/m
2).Therewasahighprevalence
of cardiometabolic risk factors, including
abdominal obesity, low HDL cholesterol,
hypertriglyceridemia, high LDL choles-
terol, and hypertension (Table 1).
Mean A1C reduction from baseline
was signiﬁcantly greater with rimonabant
versus placebo (0.8 vs. 0.3%, respec-
tively;P0.0002)(Table2,Fig.1A).The
effect of rimonabant on A1C was more
pronounced in a subset of patients with
baseline A1C 8.5% (1.9 vs. 0.7%,
respectively; P  0.0009) (Table 2). At
studyend,morepatientsreceivingrimon-
abant than patients receiving placebo
achieved A1C 7.0% (51 vs. 35%, re-
spectively; P  0.0122) (Table 2). FPG
also improved signiﬁcantly with rimon-
abant compared with placebo (Table 2).
Body weight loss from baseline was
greater with rimonabant (6.7 kg) than
with placebo (2.8 kg) at 6 months (
3.84kg;P0.0001)(Table2,Fig.1B),
with parallel improvements in waist cir-
cumference (6 vs. 2 cm; P  0.0001)
(Fig. 1C). In patients with BMI 27
kg/m
2 at baseline, treatment effects on
A1C, weight, and waist circumference
were similar to those observed in the
overall population (0.9 vs. 0.4%,
P  0.0009; 7.0 vs. 2.9 kg, P 
0.0001; and 6.4 vs. 2.4 cm, P 
0.0001, for the rimonabant and placebo
groups, respectively).
HDL cholesterol increased with a
treatment difference of 7% (P 
0.0001) and triglycerides improved by
17% (P  0.0031) in favor of rimon-
abant (Table 2, Fig. 1D and E). Rimon-
abant was also associated with signiﬁcant
reductions in non-HDL cholesterol (Ta-
ble 2), total cholesterol–to–HDL choles-
terol ratio, and apolipoprotein B–to–
apolipoprotein A1 ratio (supplemental
Table A, available in the online appen-
dix). Total cholesterol and LDL choles-
terol did not change, although the mean
size of LDL particles increased signiﬁ-
cantly with rimonabant relative to pla-
cebo (Table 2). Signiﬁcant improvements
occurredwithrimonabantversusplacebo
in levels of adiponectin (Table 2, Fig. 1F),
HOMA-IR, proinsulin-to-insulin ratio
(Table2),andproinsulinandleptinlevels
(supplemental Table A). Alanine amino-
transferase levels were reduced by 6.3
IU/l (P  0.0074) in favor of 20 mg
rimonabant. Systolic and diastolic blood
pressures, heart rate, renal function, and
urinary albumin-to-creatinine ratio were
not affected by rimonabant.
Table 2—Continued
Placebo 20 mg rimonabant P value vs. placebo
LDL particle size (Å)
n 129 126
Mean baseline* 268.6  4.7 268.3  5.6
Mean % change vs. baseline* –0.0  1.6 0.6  1.7
LS Mean % change vs. placebo† — 0.61  0.18 0.0008
Non-HDL cholesterol (mmol/l)
n 131 130
Mean baseline* 3.78  0.95 3.99  1.14
Mean % change vs. baseline* 2.72  26.42 –4.64  19.55
LS mean % change vs. placebo† — –5.535  2.763 0.0462
Total cholesterol (mmol/l)
n 131 130
Mean baseline* 5.07  0.96 5.31  1.14
Mean % change vs. baseline* 2.01  17.25 –1.43  15.09
LS mean % change vs. placebo† — –1.961  1.903 0.3037
Data are means  *SD or †SE or percent (n). Mean changes versus placebo are least-squares (LS) mean changes from the ANCOVA analysis (see RESEARCH DESIGN
AND METHODS). Data are from the ITT population (last observation carried forward) excluding postrescue medication data.
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adiponectin(F)over6monthsintheintention-to-treatpopulationwithlastobservationcarriedforward.Ewithdottedline,placebo;Fwithregular
line, rimonabant.
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by weight loss interaction, a prespeciﬁed
linear regression analysis within the
ANCOVA model used for the primary
analysis suggested that 57% of the placebo-
corrected improvement in A1C in the
overall rimonabant group was not attrib-
utable to body weight changes during
treatment. Including weight loss in the
ANCOVA model resulted in an adjusted
effect on A1C of 0.29% for rimonabant
versus placebo (P  0.0418); excluding
weight loss also resulted in a signiﬁcant
unadjusted effect on A1C for rimonabant
versusplacebo(0.51%;P0.0002).In
the 29 patients who were not overweight
(BMI 27 kg/m
2), the A1C treatment ef-
fect of rimonabant was 0.78% versus
placebo, despite weight loss of only
0.53 kg. Furthermore, analysis of A1C
by three categories of percent body
weight loss also suggested a weight-
independent effect (supplemental Table
B, available in the online appendix). Lin-
ear regression analysis also indicated that
the effects of rimonabant on FPG, HDL,
triglycerides, and adiponectin were not
accounted for by weight loss alone.
Safety and tolerability data (Table 3)
showed that the most common adverse
events in rimonabant-treated patients
were dizziness, nausea, upper respiratory
tract infection, anxiety, and depressed
mood; these were mostly mild or moder-
ateinseverity.Overall,24of138(17.4%)
patients receiving rimonabant experi-
enced a psychiatric disorder versus 15 of
140 (10.7%) patients receiving placebo.
Within the psychiatric system, anxiety
and depressed mood were reported more
frequently with rimonabant than with
placebo, although depression occurred
more frequently with placebo than with
rimonabant (2.9 vs. 1.4%, respectively).
One patient in the rimonabant group
(0.7%) reported suicide ideation, judged
by the investigator to be a symptom of
depressedmood;nocasesofattemptedor
completed suicide were reported. Hypo-
glycemia was uncommon: one patient in
each group reported a single, mild hypo-
glycemicevent.Ahigherrateoftreatment
discontinuation due to adverse events
largely accounted for a higher overall
dropout rate in the rimonabant group
(Table 3). A total of 20 severe adverse
events were experienced by ﬁve patients
from the placebo group and nine patients
from the rimonabant group and were
judged by the investigators as probably
notbeingrelatedtothestudymedication.
Table 3—Summary of adverse events at 6 months in randomly assigned and exposed patients
Treatment-emergent adverse events
occurring with an incidence of 2% in
the rimonabant treatment group listed by
preferred term* Placebo
20 mg
rimonabant
n 140 138
Any adverse event 81 (57.9) 97 (70.3)
Dizziness 3 (2.1) 15 (10.9)
Nausea 5 (3.6) 12 (8.7)
Nasopharyngitis 11 (7.9) 10 (7.2)
Upper respiratory tract infection 3 (2.1) 10 (7.2)
Anxiety 5 (3.6) 8 (5.8)
Depressed mood 1 (0.7) 8 (5.8)
Diarrhea 6 (4.3) 6 (4.3)
Vertigo 1 (0.7) 6 (4.3)
Vomiting 1 (0.7) 6 (4.3)
Asthenia 1 (0.7) 5 (3.6)
Headache 9 (6.4) 5 (3.6)
Anorexia 0 4 (2.9)
Back pain 4 (2.9) 4 (2.9)
Fall 3 (2.1) 4 (2.9)
Fatigue 1 (0.7) 4 (2.9)
Paresthesia 2 (1.4) 4 (2.9)
Sinusitis 2 (1.4) 4 (2.9)
Vision blurred 0 4 (2.9)
Arthralgia 4 (2.9) 3 (2.2)
Dry mouth 0 3 (2.2)
Hypoesthesia 0 3 (2.2)
Inﬂuenza 2 (1.4) 3 (2.2)
Insomnia 3 (2.1) 3 (2.2)
Pain 1 (0.7) 3 (2.2)
Shoulder pain 1 (0.7) 3 (2.2)
Somnolence 0 3 (2.2)
Visual acuity reduced 0 3 (2.2)
Adverse events leading to permanent
study discontinuation
Overall dropout rate 15 (10.7) 27 (19.6)
Any serious adverse event† 5 (3.6) 9 (6.5)
Discontinuation due to any adverse
event‡
3 (2.1) 13 (9.4)
Psychiatric disorders
Any psychiatric adverse event 0 7 (5.1)
Depressed mood 0 3 (2.2)
Nervous system disorders
Any nervous system adverse event 0 5 (3.6)
Paresthesia 0 3 (2.2)
Dizziness 0 2 (1.4)
Hyposmia 0 2 (1.4)
Gastrointestinal disorders
Any gastrointestinal system adverse
event
1 (0.7) 4 (2.9)
Metabolism and nutrition disorders
Any adverse event related to
metabolism or nutrition
0 2 (1.4)
Anorexia 0 2 (1.4)
Dataaren(%).Onepatientcanreportseveralevents.*DeﬁnedaccordingtotheMedDRAclassiﬁcation.†One
patient died (during treatment with placebo) as a result of a subdural hemorrhage due to a meningioma.
‡AccordingtoMedDRA,atleasttwopatientsinanyrimonabantgroupandonlyinmainsystemorganclasses
(1%).
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selective CB1 receptor antagonism with
rimonabant signiﬁcantly improved A1C
to a clinically meaningful level close to
therapeutictargets,withagreatereffectin
patients with more severe hyperglycemia
at baseline. Furthermore, 50% of pa-
tients treated with rimonabant achieved
A1C of 7.0%.
Notably, the rimonabant-induced
weight loss of 6.7 kg from baseline can
also be considered clinically meaningful
inlightoftheconcomitantA1Creduction
of 0.8% from baseline. Acute caloric re-
strictionitself,independentofweightloss
(18,19), may have contributed, at least
initially, to some of the metabolic im-
provements observed in SERENADE, but
rimonabant-induced weight loss proba-
bly contributed signiﬁcantly to the A1C
reduction (7). However, linear regression
analysis suggested that about half of the
effect of rimonabant on A1C was inde-
pendent of body weight changes, consis-
tent with improved glycemic control
observed in those patients not losing
weight. Indeed, patients with BMI 27
kg/m
2 had minimal weight loss with
rimonabant and still had an A1C reduc-
tion of 0.8%. Controlled pair-feeding
studies or studies in normal-weight pa-
tients may conﬁrm the weight-indepen-
dent effects of rimonabant.
Preclinical studies with rimonabant
demonstrated multiple peripheral meta-
bolic effects, including reduced lipogene-
sisandfreefattyacidsynthesispreventing
hepatic fat accumulation, increased adi-
ponectin release, and improved skeletal
muscle glucose uptake (12, 20–24).
These would favorably impact type 2 dia-
betes–related metabolic abnormalities.
Signiﬁcant reductions in levels of alanine
aminotransferase, a marker of fatty liver
disease, and increased adiponectin levels
observed in SERENADE suggested a po-
tentially beneﬁcial effect of rimonabant
on insulin resistance.
SERENADE conﬁrmed and extended
theﬁndingsoftheRimonabantinObesity
(RIO)-Diabetes study of rimonabant in
overweight/obese patients with type 2 di-
abetes suboptimally controlled using
metformin or sulfonylurea monotherapy
(15). The RIO-Diabetes study demon-
strated signiﬁcant reductions in body
weight (primary outcome) and a mean-
ingful placebo-subtracted A1C reduction
(secondary outcome) of 0.7% from a
baseline of 7.3%. Improvements in car-
diometabolic risk factors in SERENADE
were similar to the 1-year interim results
of the Look AHEAD (Action for Health in
Diabetes) study designed to determine
the impact of intentional weight loss in
reducing cardiovascular events in type 2
diabetes(25).However,theLookAHEAD
study used an intensive lifestyle program
withweeklygroupmeetingsandmonthly
individual sessions comprising dietary
modiﬁcations (meal replacements, frozen
foods,andstructureddiets)andincreased
physical exercise (up to 175 min/week)
directed by a multidisciplinary team of
dietitians, behavioral psychologists, and
exercise specialists. Investigators could
also initiate weight loss medication and
adjustments in blood pressure–, lipid-,
andglucose-loweringmedicationsattheir
discretion. Therefore, direct comparisons
between results from the Look AHEAD
study and SERENADE are difﬁcult.
The safety proﬁle of 20 mg rimon-
abantinSERENADEwassimilartothatin
RIO-Diabetes,withthemostcommonad-
verse events arising in the psychiatric,
neurological, and gastrointestinal sys-
tems. Most adverse events were mild or
moderate in severity in both SERENADE
and RIO-Diabetes (15). The incidence of
psychiatric disorders was higher with
rimonabant versus placebo, and more pa-
tients receiving rimonabant experienced
anxiety or depressed mood versus pla-
cebo. Type 2 diabetes itself, like many
chronic diseases, is associated with an in-
creased incidence of depression. It is cur-
rently recommended that rimonabant
should not be used in patients with a his-
tory of depression, and these potential
side effects need to be closely monitored
in clinical practice. Further comprehen-
sive safety assessments using validated
neuropsychiatric tools (e.g., the Colum-
bia Classiﬁcation Algorithm for Suicide
Assessment) in completed and ongoing
studieswithrimonabantwillbetterestab-
lish its beneﬁt-to-risk proﬁle.
Insummary,thisstudydemonstrated
that 20 mg rimonabant improved glyce-
mic control and reduced body weight,
with beneﬁcial effects on the lipid proﬁle,
in drug-naive patients, consistent with
previous observations in patients receiv-
ing metformin or sulfonylurea. Ongoing
clinical trials of rimonabant plus met-
formin compared with other treatment
options will evaluate the potential role of
rimonabant, an agent with a novel mech-
anism of action, in patients with type 2
diabetes (26). Further characterization of
the safety proﬁle of rimonabant to better
understandthebeneﬁt-to-riskproﬁlewill
emerge from long-term cardiovascular
outcome trials as well as controlled stud-
ies exploring different potential drug
combinations between rimonabant and
other antidiabetic therapies.
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